## CLEAN VERSION OF EACH REPLACEMENT PARAGRAPH/SECTION/CLAIM AND INSTRUCTIONS FOR ENTRY

## **IN THE SPECIFICATION:**

As a result of these procedures, the disease specific marker fibronectin precursors having a molecular weight of about 1356.65 daltons and a sequence of SEQ ID NO: 1, a molecular weight of about 1625.84 daltons having a sequence of SEQ ID NO: 2, a molecular weight of about 1818.97 having a sequence of SEQ ID NO: 3, and a molecular weight of about 1629.8713 having a sequence of SEQ ID NO: 4 were found to be predictive of Alzheimers disease.

## IN THE CLAIMS:

particular disease state.

- 1. A biopolymer marker selected from the group consisting of SEQ ID NO: 1, SEQ ID NO:
- 2, SEQ ID NO: 3, SEQ ID NO: 4 or at least one analyte thereof useful in indicating at least one
- 18. A kit for diagnosing, determining risk-assessment, and identifying therapeutic avenues related to a disease state comprising:

at least one biochemical material which is capable of specifically binding with a biomolecule which includes at least one biopolymer marker selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4 or an analyte thereof related to said disease state; and

means for determining binding between said biochemical material and said biomolecule;

D2 cont.

whereby at least one analysis to determine a presence of a marker, analyte thereof, or a biochemical material specific thereto, is carried out on a sample.

29. Polyclonal antibodies produced against a marker selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4 or an analyte thereof in at least one animal host.

Je Co

- 30. An antibody that specifically binds a biopolymer including a marker selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4 or at least one analyte thereof.
- 33. A process for identifying therapeutic avenues related to a disease state comprising: conducting an analysis as provided by the kit of claim 18; and interacting with a biopolymer selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4 or at least one analyte thereof; whereby therapeutic avenues are developed.

04

34. The process for identifying therapeutic avenues related to a disease state in accordance with claim 33, wherein said therapeutic avenues regulate the presence or absence of the biopolymer selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4 or at least one analyte thereof.